Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

SYNECTICS PLC Director's Dealing 2019

May 23, 2019

7942_dirs_2019-05-23_e6d3787b-902e-48f4-ad12-1608f49cf2b2.html

Director's Dealing

Open in viewer

Opens in your device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 0228A

Synectics PLC

23 May 2019

Synectics plc

("Synectics" or the "Company")

Director/PDMR dealings

23 May 2019

Synectics (AIM: SNX), a leader in the design, integration, control and management of advanced surveillance technology and networked security systems, has been notified that the Trustee of the Company's HMRC Approved Employee Share Acquisition Plan ("ESAP") reinvested the Company's final dividend and purchased on 22 May 2019 1,057 ordinary shares of 20 pence each in the Company ("Shares") at £1.91495 per Share in accordance with the ESAP's rules.

As a result of this purchase, the Company has been notified that Paul Webb, Chief Executive Director, has acquired an interest in 126 Shares and that Greg Alcorn, a PDMR of the Company, has acquired an interest in 26 Shares.

Following this purchase by the ESAP, the interests of Paul Webb and Greg Alcorn in Shares are as follows:

Name Shares Held Interest in Shares in Share Schemes Resultant Total Interest % of Issued Share Capital
Paul Webb 52,115 247,497 299,612 1.68%
Greg Alcorn - 11,873 11,873 0.07%

For further information, please contact:

Synectics plc

Claire Stewart, Company Secretary

Tel: +44(0) 1527 850 080

Stockdale Securities

Tom Griffiths / Henry Willcocks

Tel: +44 (0) 20 7601 6100

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

DSHEAFSDALANEFF